Chemistry:Onapristone
 | |
| Clinical data | |
|---|---|
| Other names | ZK-89299; ZK-299; AR-18; IVV-1001; 11β-(4-(Dimethylamino)phenyl)-17α-hydroxy-17β-(3-hydroxypropyl)-13α-estra-4,9-dien-3-one |
| Drug class | Antiprogestogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H39NO3 |
| Molar mass | 449.635 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Onapristone (INN) (developmental code names ZK-89299, ZK-299) is a synthetic and steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering[1] and described in 1984 but was never marketed.[2][3] It is a silent antagonist of the progesterone receptor (PR), in contrast to the related antiprogestogen mifepristone (which is a weak partial agonist of the receptor).[4] Moreover, compared to mifepristone, onapristone has reduced antiglucocorticoid activity, shows little antiandrogenic activity, and has 10- to 30-fold greater potency as an antiprogestogen.[4] The medication was under development for clinical use, for instance in the treatment of breast cancer and as an endometrial contraceptive, but was discontinued during phase III clinical trials in 1995 due to findings that liver function abnormalities developed in a majority patients.[5][6][7]
Onapristone has been found to be effective in the treatment of breast cancer.[8][5][9]
As of 2016, onapristone has re-emerged and is under development for the treatment of prostate cancer, currently in phase II clinical trials.[10] It was also under development for the treatment of endometrial cancer, breast cancer, ovarian cancer, and uterine cancer, but was discontinued for these indications in favor of focusing on prostate cancer.[10]
See also
- List of investigational sex-hormonal agents § Progestogenics
- Aglepristone
- Lilopristone
- Telapristone
- Toripristone
References
- ↑ "Progesterone receptor action: translating studies in breast cancer models to clinical insights". Advances in Experimental Medicine and Biology. 630. Springer. 2008. pp. 94–111. doi:10.1007/978-0-387-78818-0_7. ISBN 978-0-387-78817-3. Onapristone, p. 102, at Google Books
- ↑ "O". Dictionary of Drugs. Springer. 1990. pp. 892–927. doi:10.1007/978-1-4757-2085-3_15. ISBN 978-1-4757-2087-7. Onapristone, p. 903, at Google Books
- ↑ "O". Concise Dictionary of Pharmacological Agents. Springer. 1999. pp. 206–213. doi:10.1007/978-94-011-4439-1_14. ISBN 978-94-010-5907-7. Onapristone, p. 207, at Google Books
- ↑ 4.0 4.1 "Antiestrogen Resistance in Human Breast Cancer". Estrogens, Progestins, and Their Antagonists. Hormones in Health and Disease. Birkhäuser. 1997. pp. 115–160. doi:10.1007/978-1-4612-4096-9_5. ISBN 978-1-4612-8650-9. Onapristone, p. 134, at Google Books
- ↑ 5.0 5.1 "Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer". European Journal of Cancer 35 (2): 214–218. February 1999. doi:10.1016/S0959-8049(98)00388-8. PMID 10448262.
- ↑ "Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception". American Journal of Obstetrics and Gynecology 173 (3 Pt 1): 779–787. September 1995. doi:10.1016/0002-9378(95)90341-0. PMID 7573244.
- ↑ "Endocrine Therapy". Management of Breast Diseases. Springer. 2010. pp. 329–352. doi:10.1007/978-3-540-69743-5_18. ISBN 978-3-540-69742-8. Onapristone, p. 338, at Google Books
- ↑ "Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer". Steroids 65 (10–11): 825–830. 2000. doi:10.1016/S0039-128X(00)00195-1. PMID 11108894.
- ↑ "Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers". PLOS ONE 13 (10): e0204973. 2018. doi:10.1371/journal.pone.0204973. PMID 30304013. Bibcode: 2018PLoSO..1304973C.
- ↑ 10.0 10.1 "Onapristone - Context Therapeutics". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800000877.
 |  |
